A Controlled Trial on the Value of Prochlorperazine, Trifluoperazine and Intensive Group Treatment

1963 ◽  
Vol 109 (461) ◽  
pp. 510-522 ◽  
Author(s):  
M. Hamilton ◽  
A. Hordern ◽  
F. N. Waldrop ◽  
J. Lofft
Keyword(s):  
Group Treatment ◽  
Controlled Trial ◽  
Psychotropic Agents ◽  
Intensive Group

The importance of non-drug factors in the response of patients treated with psychotropic agents has been widely commented upon in recent years, though very few investigations have been undertaken specifically to identify and study these factors and to determine their role in pharmacotherapy (Hamilton and Hordern, 1963).

The Use of Self-Directed Relapse Prevention Booklets to Assist in Maintaining Abstinence After a 6-Week Group Smoking Cessation Treatment Program: A Randomized Controlled Trial

2017 ◽  
Vol 45 (2) ◽  
pp. 190-197 ◽  
Author(s):  
Susan Veldheer ◽  
Shari Hrabovsky ◽  
Jessica Yingst ◽  
Chris Sciamanna ◽  
Arthur Berg ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Treatment Program ◽  
Group Treatment ◽  
Relapse Prevention ◽  
Smoking Status ◽  
Controlled Trial ◽  
Treatment Method ◽  
Smoking Cessation Treatment ◽  
Cessation Treatment ◽  
Intensive Group

Background. Identifying effective relapse prevention interventions is a vital step to help smokers maintain abstinence for the long term. Aims. The purpose of this study is to determine if providing recently quit smokers with self-directed relapse prevention booklets is effective at maintaining abstinence after intensive group smoking cessation treatment. Method. Two hundred and twenty-five participants were randomized to receive Forever Free (FF) relapse prevention booklets or a control booklet (Surgeon General’s report, SG) at the end of a 6-week group treatment program. Participants were then contacted by phone to assess whether they had read the materials. Smoking status was assessed 6 months after their target quit date. Primary analyses focused on the 115 participants who quit at the end of treatment. Results. There was no difference in the 6-month quit rate between groups (40.7% quit FF vs. 44.6% quit SG, p = .67). The FF group read a significantly smaller proportion of the materials versus the control booklet (20.0% read most or all of FF vs. 72.0% of SG, p < .001). Conclusion. Forever Free self-directed relapse prevention booklets did not reduce relapse or enhance cessation over general tobacco and health information when added to intensive group smoking cessation treatment. However, this study lacked power to detect a small but clinically meaningful positive effect.

PAI Factors and Intensive Group Treatment Success

2010 ◽  
Author(s):  
Nancy A. Kennedy ◽  
Glen E. Getz ◽  
Sarah Thompson
Keyword(s):  
Group Treatment ◽  
Treatment Success ◽  
Intensive Group

scholarly journals A Randomized Controlled Trial Evaluating Integrative Psychotherapeutic Group Treatment Compared to Self-Help Groups in Functional Vertigo/Dizziness

2021 ◽  
Vol 10 (10) ◽  
pp. 2215
Author(s):  
Karina Limburg ◽  
Katharina Radziej ◽  
Heribert Sattel ◽  
Peter Henningsen ◽  
Marianne Dieterich ◽  
...  
Keyword(s):  
Group Treatment ◽  
Mixed Model ◽  
Linear Mixed Model ◽  
Controlled Trial ◽  
Clinical Psychologist ◽  
Control Group ◽  
Attrition Rates ◽  
Randomized Controlled ◽  
Self Help ◽  
Self Help Groups

We tested the efficacy of an integrative psychotherapeutic group treatment (IPGT) in reducing vertigo/dizziness-related impairment along with depression, anxiety, and somatization by conducting a randomized controlled superiority trial comparing IPGT to self-help groups moderated by a clinical psychologist (SHG). Adult patients with functional vertigo and dizziness symptoms were randomly allocated to either the IPGT or SHG as active control group. Outcomes were assessed at baseline (t0), after treatment lasting 16 weeks (t1), and 12 months after treatment (t2). A total of 81 patients were assigned to IPGT and 78 patients were assigned to SHG. Vertigo-related impairment was reduced in both conditions (IPGT: t0–t1: d = 1.10, t0–t2: d = 1.06; SHG: t0–t1: d = 0.86, t0–t2: d = 1.29), showing the efficiency of both IPGT and SHG. Clinically relevant improvements were also obtained for depression in both groups. Linear mixed model analyses revealed no differences between groups for all outcomes (effect of group for the primary outcome: b = −1.15, SE = 2.13, t = −0.54, p = 0.59). Attrition rates were higher in SHG (52.6%) than in IPGT (28.4%). Both conditions improved primary and secondary outcomes while IPGT was better accepted by patients than SHG. Trial registration: ClinicalTrials.gov, Identifier: NCT02320851.

Effect of a Novel Thermostatic Device on Meibomian Gland Dysfunction: A Randomized Controlled Trial in Chinese Patients

2021 ◽  
Author(s):  
Siyuan Li ◽  
Ke Yang ◽  
Jingyi Wang ◽  
Shang Li ◽  
Lei Zhu ◽  
...  
Keyword(s):  
Group Treatment ◽  
Controlled Trial ◽  
Anterior Segment ◽  
Meibomian Gland ◽  
Chinese Patients ◽  
Meibomian Gland Dysfunction ◽  
Controlled Clinical Trial ◽  
Randomized Controlled ◽  
Meibomian Glands ◽  
Thermostatic Device

Abstract BackgroundAs a chronic disease, meibomian gland dysfunction (MGD) which causes excessive evaporation of tears by changing the tear film composition, is considered a leading cause of dry eye. Although a variety of physical therapy equipment, there is currently no economical and effective treatment for MGD. The aim of this study was to evaluate the effectiveness and safety of the MiBoFlo Thermoflo® (Mibo Medical, Dallas, TX, USA), a new thermostatic device, on both objective symptoms and subjective signs in Chinese MGD patients.MethodsThis was a prospective, randomized, controlled clinical trial. 108 eyes of 54 MGD patients in Beijing Tongren Hospital were recruited and randomized 1:1 to MiBoFlo (n = 54 eyes) or LipiFlow® (TearScience, Morrisville, NC, USA) (n = 54 eyes) treatment group. In the MiBoFlo group, treatment for each eye took 10 minutes and proceeded every two weeks for a total of three times. Patients in the LipiFlow group received a single 12-minute treatment. Main Outcome Measures: The primary outcomes include changes in Ocular Surface Disease Index (OSDI) score, Meibomian Glands Yielding Liquid Secretion (MGYLS) score and Meibomian Glands Secretion (MGS) score from baseline to 2 months. The secondary outcomes include Tear Meniscus Height (TMH), Non-invasive Keratograph Break-up Time (NIKBUT), Corneal Fluorescein Staining (CFS) and Meibomian Glands (MG) loss from baseline to 2 months. Safety outcomes include visual acuity (VA), intraocular pressure (IOP), anterior segment and facial skin.ResultsThe OSDI score, MGYLS score and MGS score all improved from baseline to 1 month in both MiBoFlo and LipiFlow group, and these improvements were maintained at 2 months. CFS score, NIKBUT and MG loss had no significant change in both groups. CFS score improvement in MiBoFlo group were significantly more obvious than in LipiFlow group in the follow-up visit (p<0.01).ConclusionAs a portable and comfortable device, MiBoFlo treatment can offer an advancement for the treatment of MGD and a course of treatment results in at least two months of sustained improvement in both symptoms and meibomain gland function.

scholarly journals Social cognitive group treatment for impaired insight in psychosis: A multicenter randomized controlled trial

2019 ◽  
Vol 206 ◽  
pp. 362-369 ◽  
Author(s):  
G.H.M. Pijnenborg ◽  
A.E. de Vos ◽  
M.E. Timmerman ◽  
M. Van der Gaag ◽  
B.E. Sportel ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Group Treatment ◽  
Social Cognitive ◽  
Controlled Trial ◽  
Randomized Controlled ◽  
Multicenter Randomized Controlled Trial
Sign in / Sign up

Export Citation Format

Share Document